PREVALENCIA DE HEMORRAGIA DIGESTIVA ALTA POSTERIOR A TERÁPIA FIBRINOLITICA POR INFARTO AGUDO AL MIOCARDIO EN EL HOSPITAL GENERAL REGIONAL 1 QUERETARO DEL PERIODO ENERO 2008 A DICIEMBRE 2010

Abstract

To determine the prevalence of gastrointestinal bleeding in patients receiving thrombolytic therapy after myocardial infarct treated at the HGR No. 1 Queretaro. MATERIAL AND METHODS: The retrospective, observational study in 129 individuals in the No 1 IMSS HGR Qro, who were admitted to intensive care in the period January 2008 to December 2010 including patients both sexes, from the 3rd decade of life onwards those who received fibrinolytic therapy recently Myocardium infarct and had gastrointestinal bleeding for the first time, after this treatment, we excluded patients with gastrointestinal bleeding due to other causes (liver disease, blood disorders, etc.) RESULTS: Of the 129 patients predominated males 84.4% (109 patients), 5.4% (7 patients) with risk factors for bleeding, 2.3% (3 patients) had oral bleeding, gastrointestinal bleeding and 0% being the most used fibrinolytic Tecneteplase 48.8% (63 patients), streptokinase, 38.7% (50 patients), alteplase 7.7% (10 patients) and 4.6% (6 patients) was not determined fibrinolytic employee. The myocardial area most affected in this patient group was lower than 26.35% (34 patients). CONCLUSIONS: Myocardial infarction is a severe disease, whose diagnosis and treatment with pharmacological reperfusion therapy is crucial for the prognosis of the patient: a complication of this treatment the bleeding at any level, this study found that the prevalence of bleeding in patients was low (3.8) therefore remains the first choice treatment in patients with myocardial infarction with ST-segment positive difference within the first 12 hours of onset of angina